Shots:

• J&J launches a multi-pronged response to the Coronavirus (2019-nCoV or Wuhan coronavirus) outbreak and collaborating with others to screen a library of antiviral therapies
• The vaccine program leverages Janssen’s AdVac and PER.C6 technologies- providing the ability to rapidly upscale production of the optimal vaccine therapy. The company utilize its same technology in its Ebola vaccine- currently being administered in the Democratic Republic of Congo and Rwanda
• Additionally- Janssen has denoted 300 boxes of Prezcobix (darunavir/cobicistat) to the Shanghai Public Health Clinical Center and Zhongnan Hospital of Wuhan University to support efforts in finding a solution against the 2019-nCoV and 50 boxes to the Chinese Center for Disease Control and Prevention for laboratory-based investigations

Click here ­to­ read full press release/ article | Ref: Johnson & Johnson | Image: NYTimes